Lilly once again beats expectations as tirzepatide accounts for 64% of revenue

Summary

Eli Lilly reported Q2 2026 revenues of $23 billion, exceeding analyst expectations by approximately $3 billion, with tirzepatide generating 64% of revenue. The company raised its full-year revenue guidance to $85-87 billion.